Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.

Pillai, G; Fourie, P B; Padayatchi, N; Onyebujoh, P C; McIlleron, H; Smith, P J; Gabriels, G

Pillai, G; Fourie, P B; Padayatchi, N; Onyebujoh, P C; McIlleron, H; Smith, P J; Gabriels, G.

Affiliation

Pillai G; Department of Pharmacology, University of Durban Westville, South Africa. cpillai@pixie.udw.ac.za

Int J Tuberc Lung Dis ; 3(11 Suppl 3): S309-16; discussion S317-21, 1999 Nov.

Article in En | MEDLINE | ID: mdl-10593710

Subject(s)

Antibiotics, Antitubercular/administration & dosage; Antibiotics, Antitubercular/pharmacokinetics; Rifampin/administration & dosage; Rifampin/pharmacokinetics; Tuberculosis/drug therapy; Antibiotics, Antitubercular/blood; Antitubercular Agents/administration & dosage; Area Under Curve; Biological Availability; Cross-Over Studies; Drug Combinations; Humans; Male; Rifampin/blood; Therapeutic Equivalency; Tuberculosis/prevention & control

Search on Google

XML

PubMed Links

Collection: 01-internacional Health context: 1_ASSA2030 / 2_ODS3 / 3_ND Database: MEDLINE Main subject: Rifampin / Tuberculosis / Antibiotics, Antitubercular Type of study: Clinical_trials / Prognostic_studies Limits: Humans / Male Language: En Journal: Int J Tuberc Lung Dis Year: 1999 Document type: Article

Search on Google

XML

PubMed Links